RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Goldman Sachs Alternatives
G

Goldman Sachs Alternatives portfolio

Goldman Sachs Alternatives has 17 portfolio companies on record at Recent Funding, with 12 investments in the last 12 months.

Type: Investor.
Portfolio on Recent Funding: 17.
Deals, last 12 months: 12.
Rounds led: 11 of 18.
Capital in their rounds: $2.87B.
Latest deal: Cyera · Sep 22, 2026.
About this page

It led 11 of the 18 rounds it joined. Its most recent investment on record is Cyera's $400M Series B+ round in September 2026, which it led. By category, its portfolio leans toward Health and bio (5) and Fintech (4). It has co-invested with Omega Funds, Sequoia and T. Rowe Price, most often Omega Funds (3 rounds).

What Goldman Sachs Alternatives invests in

Goldman Sachs Alternatives recent investments

CompanyRoundDateAlongside
CCyeraSeries B+ · $400M · leadnone named
HHarveySeries B+ · $550MVerified Capital, Sapphire Ventures, Evantic Capital +6
SSocureSeries B+ · $156MSummit Partners (lead), Docusign, Wells Fargo
VVaderis TherapeuticsSeries B+ · $152M · leadKalehua Capital, EQT Life Sciences, Droia Ventures +4
SSpectro CloudSeries B+ · $100M · leadLG Technology Ventures, AMD Ventures, Maximus +1
AAidocSeries B+ · $150M · leadSoftBank Investment Advisers, TLV Partners, TCV +4
KKashableSeries B+ · $60M · leadRevolution, Citi Impact Fund, EJF Ventures
TThird Arc BioSeries A · $52MAberdeen, Marshall Wace, Galapagos +6

How Goldman Sachs Alternatives invests

StageDealsCapital in rounds
Series B+ 15 83%$2.45B
Series A 3 17%$417M
YearDealsCapital in rounds
2024 3 17%$240M
2025 5 28%$380M
2026 10 56%$2.25B

Goldman Sachs Alternatives portfolio companies

CompanyRound with Goldman Sachs AlternativesTotal raisedLatest raise
CCyera
Legal and compliance
Series B+ · $400M · lead$2.7BSep 22, 2026
Series B+
HHarvey
AI agents
Series B+ · $550M$1.15BSep 21, 2026
Series B+
SSocure
ZK and privacy
Series B+ · $156M$784.9MAug 27, 2026
Series B+
VVaderis Therapeutics
Health and bio
Series B+ · $152M · lead$152MAug 11, 2026
Series B+
SSpectro Cloud
Developer tools and cloud
Series B+ · $100M · lead$222.5MAug 1, 2026
Series B+
AAidoc
Health and bio
Series B+ · $150M · lead$373MApr 29, 2026
Series B+
KKashable
Fintech
Series B+ · $60M · lead$85.6MApr 27, 2026
Series B+
TThird Arc Bio
Health and bio
Series A · $52M$217MFeb 4, 2026
Series A
RRedwood Materials
AI infrastructure and compute
Series B+ · $425M$3.02BJul 31, 2026
round
AAirNexis Therapeutics
Health and bio
Series A · $200M$200MJan 9, 2026
Series A
NNeural Concept
Education
Series B+ · $100M · lead$136.1MDec 18, 2025
Series B+
FFederato
Insurance
Series B+ · $100M · lead$180MNov 18, 2025
Series B+
MMoEngage
AI coding and devtools
Series B+ · $60M · lead$238.25MDec 21, 2025
Series B+
SSimetrik
Fintech
Series B+ · lead$55MJun 4, 2025
Series B+
BBestow
AI agents
Series B+ · $120M · lead$257.5MMay 13, 2025
Series B+
VVanta
DEXs and AMMs
Series B+$40MJun 24, 2026
Seed
AAlphaSense
Data and analytics
backer$830MJun 3, 2026
round

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Share is of the 18 rounds on Recent Funding that name Goldman Sachs Alternatives. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Goldman Sachs Alternatives, which is a subset of its real portfolio. API: /api/v1/investors/goldman-sachs-alternatives (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy